Nasdaq
$20.03▼ 0.05%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $377.9MShares out 18.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 10.2After-hours26.10.03 06:024Ownership#●●●
Tectonic Therapeutic, Inc.
Insider Daniel Lochner of Tectonic Therapeutic, Inc. reported a change in beneficial ownership of securities as of September 25, 2026. This filing is a standard Form 4 notification, and no specific transaction quantities or prices were disclosed in the document.…more
$20.03-0.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 06:004Ownership
Tectonic Therapeutic, Inc.
Insider Peter McNamara of Tectonic Therapeutic, Inc. reported a change in beneficial ownership of securities as of September 25, 2026. This filing is a Form 4 statement detailing the insider's transaction.…more
$20.03-0.05%vs prev closeView filingShare - 10.2After-hours26.10.03 05:594Ownership
Tectonic Therapeutic, Inc.
Marcella K. Ruddy, an insider at Tectonic Therapeutic, Inc., filed a Form 4 on October 2, 2026, reporting a change in beneficial ownership of securities as of September 25, 2026. This filing formalizes the insider's transaction activity.…more
$20.03-0.05%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.29Pre-market26.09.29 21:00#●●●#●●●
Tectonic Therapeutic Reports Positive Phase 1a Results for HHT Candidate TX2100…more
Tectonic Therapeutic announced favorable safety and tolerability results from its Phase 1a clinical trial of TX2100 for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT). The company has received FDA Fast Track designation and plans to initiate Phase 1b and Phase 2 trials in the coming months.…more
$20.03-0.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUS